We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+57.48%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$514M
AUM Growth
-$7.79M
Cap. Flow
+$53.2M
Cap. Flow %
10.35%
Top 10 Hldgs %
56.23%
Holding
206
New
96
Increased
32
Reduced
19
Closed
50

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.5M
2
AZN icon
AstraZeneca
AZN
+$18.2M
3
MRNA icon
Moderna
MRNA
+$12.1M
4
XWEL icon
XWELL
XWEL
+$6.41M
5
CVM icon
CEL-SCI Corp
CVM
+$3.62M

Sector Composition

Rank Sector Weight
1 Miscellaneous 75.72%
2 Healthcare 15.57%
3 Consumer Staples 2.16%
4 Technology 1.81%
5 Financials 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MTC icon
26
MMTec
MTC
$482M
$3.46M 0.67%
+16,886
New +$3.44M
VTSI icon
27
VirTra
VTSI
$33.1M
$3.45M 0.67%
+561,088
New +$2.67M
AMRN
28
CALL
Amarin Corp
AMRN
$294M
$3.44M 0.67%
277
+17
+7% +$2.29K
IMG
29
DELISTED
CIMG Inc
IMG
$3.37M 0.66%
+1,379
New +$7.02M
HMCO
30
DELISTED
HumanCo Acquisition Corp. Class A Common Stock
HMCO
$3.35M 0.65%
+336,211
New +$3.5M
LFWD icon
31
ReWalk Robotics
LFWD
$20M
$3.13M 0.61%
15,380
+13,090
+572% +$3.01M
NMTR
32
PUT
DELISTED
9 Meters Biopharma
NMTR
$3.06M 0.6%
1,310
+569
+77% +$17.5K
AUTL
33
Autolus Therapeutics
AUTL
$503M
$3.01M 0.59%
+525,230
New +$3.89M
BIIB icon
34
PUT
Biogen
BIIB
$31.8B
$2.8M 0.54%
100
-1,924
-95% -$519K
ASLN
35
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.74M 0.53%
+20,429
New +$2.59M
CVM.WS
36
CALL
DELISTED
Cel-Sci Corp Series S
CVM.WS
$2.68M 0.52%
1,760
+489
+38% +$744K
ATOS icon
37
PUT
Atossa Therapeutics
ATOS
$24.2M
$2.67M 0.52%
+845
New +$30.9K
CHRN
38
ChronoScale Holdings
CHRN
$2.66B
$2.61M 0.51%
+28,224
New +$3.39M
STAB
39
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$2.51M 0.49%
+478,941
New +$2.62M
MRTX
40
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.48M 0.48%
145
IONS icon
41
Ionis Pharmaceuticals
IONS
$7.89B
$2.46M 0.48%
+54,688
New +$3.05M
RVPH
42
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$2.4M 0.47%
20,922
+3,007
+17% +$502K
XWEL icon
43
PUT
XWELL
XWEL
$7.79M
$2.39M 0.46%
648
+435
+204% +$16.6K
LSTA icon
44
PUT
Lisata Therapeutics
LSTA
$13.2M
$2.31M 0.45%
797
+790
+11,286% +$23.9K
ASXC
45
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$2.26M 0.44%
6,959
+6,104
+714% +$22.1K
ORIO
46
Orion Digital Corp
ORIO
$23.8M
$2.26M 0.44%
+88,609
New +$1.93M
CVM.WS
47
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$2.2M 0.43%
1,448
-4,055
-74% -$6.17M
ODT
48
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.17M 0.42%
634,728
+586,783
+1,224% +$11.1M
TRIL
49
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.14M 0.42%
199,569
+79,573
+66% +$984K
ASXC
50
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
$2.13M 0.41%
+6,556
New +$23.7K

Similar funds

Sabby Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sabby Management held 206 positions worth $514M, down 1.5% from $522M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sabby Management deployed $53.2M of net new capital in Q1 2021, opening 96 new positions and adding to 32 existing holdings. Its largest new stake was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.

By sector, the portfolio is most concentrated in Miscellaneous at 76% of assets, down from 81% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was AVEO Pharmaceuticals, Inc., an estimated $494K trimmed.

  • Sabby Management's largest Q1 2021 buy was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.
  • Sabby Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2021, an estimated $11.1M increase.
  • Sabby Management's biggest Q1 2021 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $494K.
  • Sabby Management fully exited Biogen in Q1 2021, selling an estimated $31.5M.
  • Sabby Management's ten largest holdings make up 56% of its $514M portfolio in Q1 2021.
  • Sabby Management opened 96 new positions and closed 50 in Q1 2021.
  • Sabby Management's portfolio value fell 1.5% quarter-over-quarter to $514M.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.